

ASPP2 deficiency causes features of 1q41q42 microdeletion syndrome

Running title: A role for ASPP2 in human congenital disorder

Jaroslav Zak¹, Virginie Vives^{1,24}, Dorota Szumska², Aude Vernet², Jurgen E. Schneider², Paul Miller¹, Elizabeth A. Slee¹, Shelagh Joss³, Yves Lacassie^{4,5}, Emily Chen⁶, Luis F. Escobar⁷, Megan Tucker⁷, Arthur S. Aylsworth⁸, Holly A. Dubbs⁹, A. Thomas Collins¹⁰, Joris Andrieux¹¹, Anne Dieux-Coeslier¹², Edda Haberlandt¹³, Dieter Kotzot¹³, Daryl A. Scott¹⁴, Michael J. Parker¹⁵, Zubaidah Zakaria¹⁶, Yew Sing Choy¹⁷, Dagmar Wieczorek^{18,19}, A. Micheil Innes²⁰, Kyung Ran Jun²¹, Samuel Zinner¹⁰, Fabrice Prin²², Craig A. Lygate², Pieter Pretorius²³, Jill A. Rosenfeld¹⁴, Timothy J. Mohun²², and Xin Lu^{1, *}

¹Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK. ²Radcliffe Department of Medicine, Division of Cardiovascular Medicine, University of Oxford, Oxford, OX3 7BN, UK. ³Queen Elizabeth University Hospital Glasgow, Glasgow, G51 4TF, UK. ⁴Department of Pediatrics, Louisiana State University, New Orleans, LA 70118, USA. ⁵Genetics Services, Children's Hospital New Orleans, New Orleans, LA 70118, USA. ⁶Kaiser Permanente, San Francisco Medical Center, San Francisco, CA 94115, USA. ⁷St Vincent Children's Hospital, Indianapolis, IN 46260, USA. ⁸Departments of Pediatrics and Genetics, University of North Carolina, Chapel Hill, NC 27599, USA. ⁹Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. ¹⁰Seattle Children's Hospital, Seattle, WA 98105, USA. ¹¹Institute of Medical Genetics, Jeanne de Flandre Hospital, CHRU de Lille, 59000, France. ¹²CHU Lille, Clinique de Génétique, Lille, F-59000, France. ¹³Innsbruck Medical University, Innsbruck, A-6020, Austria. ¹⁴Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA. ¹⁵Sheffield Children's Hospital NHS Foundation Trust, Western Bank, Sheffield, UK. ¹⁶Institute for Medical Research, Kuala Lumpur, Jalan Pahang, 50588, Malaysia. ¹⁷Prince Court Medical Centre, Kuala Lumpur, 50450, Malaysia. ¹⁸Institute of Human Genetics, University Clinic Essen, Duisburg-Essen University, Essen, 45122, Germany. ¹⁹Institute of Human Genetics, University Clinic, Heinrich-Heine University, Düsseldorf, 40225, Germany. ²⁰Department of Medical Genetics and Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, T3B 6A8, Canada. ²¹Department of Laboratory Medicine, Haeundae Paik Hospital, Inje University, Haeundae-gu, Busan, Korea. ²²The Francis Crick Institute Mill Hill Laboratory, London, NW7 1AA, UK. ²³Department of Neuroradiology, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, OX3 9DU, UK.

²⁴Current address: Centre Recherche de Biochimie Macromoléculaire, Montpellier, 34293, France.

*Correspondence should be addressed to Xin Lu: xin.lu@ludwig.ox.ac.uk; Tel: 44(0)1865617500; Fax: 44(0)1865617515. Ludwig Institute for Cancer Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, OX3 7DQ, UK

Keywords: 1q41q42 microdeletion syndrome; chromosomal abnormalities; neural tube defects; ASPP2; p53

Abbreviations: ASPP2, apoptosis-stimulating protein of p53, 2; NTD, neural tube defect; CNS, central nervous system; CAPN2, calpain 2; CAPN8, calpain 8; FBXO28, F-box only protein 28; SRO, smallest region of overlap; MRI, magnetic resonance imaging; LV, lateral ventricle; NIH, National Institutes of Health; microCT, micro-computed tomography; HREM, high-resolution episcopic microscopy; B6, C57BL6/J; VSD, ventricular septal defect; IMPC, International Mouse Phenotyping Consortium; CHARGE, Coloboma, Hear defects, Atresia of the choanae, Retardation of growth and/or development, Genital and/or urinary abnormalities, Ear abnormalities; EMT, epithelial-to-mesenchymal transition.

Abstract

Chromosomal abnormalities are implicated in a substantial number of human developmental syndromes, but for many such disorders little is known about the causative genes. The recently described 1q41q42 microdeletion syndrome is characterized by characteristic dysmorphic features, intellectual disability and brain morphological abnormalities but the precise genetic basis for these abnormalities remains unknown. Here, our detailed analysis of the genetic abnormalities of 1q41q42 microdeletion cases identified *TP53BP2*, which encodes apoptosis-stimulating protein of p53-2 (ASPP2), as a candidate gene for brain abnormalities. Consistent with this *Trp53bp2*-deficient mice show dilation of lateral ventricles resembling the phenotype of 1q41q42 microdeletion patients. *Trp53bp2* deficiency causes 100% neonatal lethality in the C57BL/6 background associated with a high incidence of neural tube defects (NTDs) and a range of developmental abnormalities such as congenital heart defects, coloboma, microphthalmia, urogenital and craniofacial abnormalities. Interestingly, abnormalities show a high degree of overlap with 1q41q42 microdeletion-associated abnormalities. These findings identify *TP53BP2* as a strong candidate causative gene for CNS defects in 1q41q42 microdeletion syndrome, and open new avenues for investigation of the mechanisms underlying CNS abnormalities.

INTRODUCTION

Chromosomal deletions that cause rare genetic disorders usually affect more than one gene and cause multiple phenotypic features. Identification of causative genes could extend our understanding of molecular pathways that are responsible for common diseases. Deletions in the chromosomal 1q41-q44 region are significantly associated with central nervous system (CNS) defects including neural tube defects (NTDs), agenesis of corpus callosum, microcephaly and hydrocephalus (1, 2). In particular, small interstitial deletions in the 1q41q42 region are implicated in the 1q41q42 microdeletion syndrome with features of severe developmental delay, intellectual disability, and brain morphological abnormalities. A critical region comprising the genes *FBXO28*, *TP53BP2*, *CAPN2* and *CAPN8* has been proposed for the 1q41q42 microdeletion syndrome based on the smallest region of overlap (3). *FBXO28* (encoding the F-box only protein 28, a ubiquitin ligase) has been proposed as a candidate gene responsible for seizures and intellectual disability in microdeletion patients (4, 5). However, the genes responsible for other phenotypes, in particular the brain morphological abnormalities, of the syndrome are unknown.

TP53BP2, which is located at the boundary of 1q41 and 1q42, encodes the Apoptosis Stimulating Protein of p53 2 (ASPP2). It is also an ankyrin repeat, SH3 domain and proline-rich containing protein (ASPP), originally identified as a positive regulator of p53-mediated transcription of apoptotic genes (6, 7). In mice, ASPP2, encoded by *Trp53bp2*, is essential for embryonic development (8, 9): an ASPP2-null genotype in mice is lethal prior to embryonic day E7 (ref. 8) and mice with homozygous deletion of exon 3 exhibit loss of neuroepithelial cell polarity and hydrocephalus (10). ASPP2 is involved in regulating apoptosis through binding to

p53 (and its sibling proteins p63 and p73) via its C-terminus and in regulating cell polarity through binding to the tight junction protein PAR3 via its N-terminus (10, 11). Both p53 and PAR3 have been implicated in NTDs (12-15) and the process of neural tube closure – which involves convergent extension and apical constriction to enable folding of a neuroepithelial sheet into the neural tube – involves apicobasal polarity and apoptosis (16-18). Therefore, we hypothesized that *TP53BP2* might contribute to the developmental abnormalities associated with 1q41q42 deletions. Through examination of ASPP2 deficiency in mice and human patients, we show that *TP53BP2* is a strong candidate for being a gene responsible for CNS defects and, potentially, other 1q4 deletion-associated phenotypes in humans.

RESULTS

***TP53BP2* deletions are associated with brain abnormalities in 1q41q42 microdeletion syndrome**

To identify the gene(s) responsible for structural brain abnormalities in 1q41q42 microdeletion syndrome, we first established the smallest region of overlap (SRO) in 1q41q42 microdeletion cases with structural brain abnormalities. To date there are 31 reported 1q41q42 microdeletion cases and 26 of them have brain MRI/CT recorded. Among the 26 cases with deletions in the 1q41q42 region for which neuroradiology reports and/or MRI scans were available, 19 were from published reports and 7 are newly identified cases (Supplementary Tables 1, 2) (ref. 3, 4, 19, 20-26). Of these 26 cases, 19 patients showed detectable structural brain abnormalities and their SRO (chr1:223 828 382-224 034 322; hg19) contains the entire coding regions of *CAPN2* and *TP53BP2*, plus exons 1 and 2 of *CAPN8*

(Figure 1) whereas in 4 of the remaining 7 cases without brain abnormalities the *TP53BP2* locus is not affected (Figure 1a and 1b).

CAPN2 and *CAPN8* encode Ca^{2+} -dependent proteases of the calpain family (27). Mice deficient in the orthologous genes *Capn2*, *Capn8* and *Trp53bp2* have been generated previously: *Trp53bp2*-deficient mice exhibit abnormalities in the central nervous system (10), whereas *Capn2*-deficient and *Capn8*-deficient mice show no abnormalities in the brain or nervous system (28-30). Publicly available data also show that *TP53BP2* is expressed more highly in the brain than all other examined tissues, whereas *CAPN2* is expressed at very low levels in the brain compared to other tissues, and *CAPN8* expression is restricted to the stomach (Figure S1a, www.gtexportal.org, (31)). Additionally, *TP53BP2* is most highly expressed in the ventricular and subventricular zones in the human embryonic brain throughout gestation, consistent with it having a key role in embryonic brain development (Figure S1b) (<http://brainspan.org>, <http://human.brain-map.org>) (32, 33). We also found no deletions of *TP53BP2* in publically available copy number data from 2 large cohorts of healthy individuals (19 584 healthy individuals (34, 35); or in an independent pediatric control group of 2 026 (ref. 36)), suggesting that *TP53BP2* deletions may be pathogenic. In contrast, 2 deletions, nsv520609 and nsv521758, spanning multiple exons of *CAPN2*, were detected in the cohort of 2 026 disease-free individuals (36). These observations suggest that *TP53BP2* is the strongest candidate for being the causative gene responsible for brain morphological abnormalities associated with 1q41q42 microdeletions.

Brain MRI reveals common ventricular abnormalities among patients with *TP53BP2* deletions

We compared structural brain phenotypes among 1q41q42 microdeletion patients with and without heterozygous *TP53BP2* deletions. Among the 22 *TP53BP2* deletion cases, the most frequently observed brain abnormality, seen in 16 out of 22 patients (73%) with heterozygous *TP53BP2* deletions, was dilation of ventricles and/or ventricular dysmorphism, frequently associated with hypoplasia or agenesis of corpus callosum (Supplementary Table 2). All 4 1q41q42 microdeletion patients without *TP53BP2* deletions showed normal ventricles (Supplementary Table 2, Figure 1b). Corpus callosum defects were observed in 10/22 (45%) of *TP53BP2*-deletion patients (5 with agenesis and 5 with hypoplasia) but in none of the patients without *TP53BP2* mutations. Cerebellar hypoplasia, encephalocele, hypomyelination, plagiocephaly, holoprosencephaly and malformations of sulcation were also observed in some *TP53BP2* deletion patients at a lower frequency (Supplementary Table 2).

For the identified 26 cases of 1q41q42 microdeletion patients, only 14 brain MRI scans were available to us and 12 of them had morphometry-compatible MRI scans (9 with *TP53BP2* deletion and 3 without) (Figure 2a). We used probabilistic morphometry to quantify the lateral ventricle (LV) volume of the 12 1q41q42 microdeletion patients (Figure 2b). 28 normal children's brain MRIs from the NIH Paediatric MRI Data Depository were used as controls (Figure 2b). As expected, LV volume was significantly larger in the *TP53BP2* deletion group (mean 33.4 ml) (Figure 2b) compared to control group (mean 10.0 ml, SD = 4.5 ml) ($p < 0.001$) and the LV volumes of microdeletion patients without *TP53BP2* deletions were within normal range (Figure 2b).

We observed defects in the ventricles of cases with *TP53BP2* deletions but not in microdeletion cases without *TP53BP2* deletions. For example, in 4 cases with

TP53BP2 deletions the bodies of the lateral ventricles appeared more parallel due to hypoplasia of the corpus callosum (Figure 2c, Supplementary Table 2: patients Case 4; Shaffer 3; Rosenfeld 8; Rosenfeld 13). This is similar but more subtle than the ventricular dysmorphism seen in association with agenesis of corpus callosum. In 3 cases the LVs were asymmetric with one side larger than the other (Figure 2c: patients Shaffer 3; Rosenfeld 12 and Wat et al 2011). These data show that *TP53BP2* deletions are associated with ventricular abnormalities that are frequently accompanied by hypoplasia of corpus callosum and/or cerebellum.

ASPP2 deficiency in mice causes CNS abnormalities with similar features to 1q41q42 microdeletion patients

We used mice with deletion of *Trp53bp2* exon 3 (*Trp53bp2*^{Δ3}) to examine how ASPP2 deficiency affects CNS development. We showed previously that the *Trp53bp2*^{Δ3/Δ3} genotype results in severe developmental defects in a strongly background-dependent manner: BALB/c *Trp53bp2*^{Δ3/Δ3} mice are born at the expected rate but most develop severe hydrocephalus before weaning, whereas only 30% of mixed C57BL/6-129Sv background (further referred to as 'mixed') *Trp53bp2*^{Δ3/Δ3} mice survive post-natally (10). On a pure C57BL/6 (referred to as B6) background, which we established by back-crossing over 10 generations, no homozygous *Trp53bp2*^{Δ3/Δ3} mice survived after birth. The surviving BALB/c *Trp53bp2*^{Δ3/Δ3} mice have a 100% incidence of hop gait. Most severe cases of neonatal hydrocephalus develop prior to birth and likely result from early defects in brain development.

To provide direct evidence that ASPP2 deficiency causes structural abnormalities in mouse embryonic brain, we used micro-computed tomography (microCT) and high-resolution episcopic microscopy (HREM) to examine *Trp53bp2*^{Δ3/Δ3} embryos. These methods allow reconstruction of 3-dimensional images as well as individual sections, showing the morphology of anatomical defects (37). At embryonic stages E13.5 and E14.5, ~50% of *Trp53bp2*^{Δ3/Δ3} BALB/c embryos exhibited enlargement of brain ventricles (Figure 3a). Subcranial and intraventricular haemorrhage were also visible by naked eye and micro-CT in 50% of *Trp53bp2*^{Δ3/Δ3} BALB/c embryos (Figure 3a, Supplementary Figure 3a, b). Brains of virtually all *Trp53bp2*^{Δ3/Δ3} embryos examined by HREM had absent or severely hypoplastic pineal gland (Figure 3b). The spinal canal of all *Trp53bp2*^{Δ3/Δ3} embryos was abnormal with stenosis (Supplementary Figure 3c), the presence of blood (Supplementary Figure 3d) or small cyst-like structures in the caudal part of the neural tube (Supplementary Figure 3e). All *Trp53bp2*^{Δ3/Δ3} embryos examined had abnormalities in the cerebrospinal fluid space with blockage and/or haemorrhage in at least one part of the ventricular system and/or spinal canal. Heterozygous (*Trp53bp2*^{Δ3/+}) embryos showed CNS abnormalities, such as spinal canal stenosis or asymmetric lateral ventricles, but with lower penetrance (Figure 3d). 25% of BALB/c *Trp53bp2*^{Δ3/+} embryos showed localised abnormalities in the distribution of neuroepithelial brain tissue associated with small patches of subcranial haemorrhage (Figure 3d). This shows that ASPP2 is required for early stages of CNS development. Interestingly, surface rendering of lateral ventricles of *Trp53bp2*^{Δ3/Δ3} embryos showed a similar shape to the dysmorphism observed in patients with *TP53BP2* deletion, with bodies of the lateral ventricles being more parallel and bulbous (Figure 3c). This suggests that ASPP2 deficiency in the

Trp53bp2^{Δ3/Δ3} mice might mimic effects of ASPP2 deficiency in humans resulting from the heterozygous deletion of *TP53BP2*.

ASPP2 deficiency causes neural tube defects in mice

ASPP2 was reported previously to control the cell polarity and cell proliferation of neural epithelial cells (10). These are two important biological processes involved in neural tube closure, an early event in CNS development the disruption of which causes NTDs. To further investigate the effect of genetic background on phenotype severity in ASPP2-deficient mice, we compared *Trp53bp2*^{Δ3/Δ3} embryos in mixed, B6 and BALB/c backgrounds. NTDs were detected in 15% (n=127) of embryos on the mixed background, 46% (n=13) on the pure B6 background and 8% (n=12) on the BALB/c background (Figure 4, Table S3). The only NTD observed in BALB/c embryos was exencephaly (Figure 4, S4a). On the mixed background, NTDs were small at the early stages (E9.5-E10.5) but progressed to larger lesions at >E13.5, and featured mainly exencephaly and rostral spina bifida (Figure 4) but rarely craniorachischisis (Figure 4-middle panel). In contrast, NTDs in *Trp53bp2*^{Δ3/Δ3} B6 embryos have a broad spectrum of phenotypes, ranging from spina bifida to craniorachischisis with some spina bifida phenotypes affecting a large section of the neural tube (Figure 4, Supplementary Figure 4b). MicroCT and HREM inspection of *Trp53bp2*^{Δ3/Δ3} embryos with NTDs revealed occasional overgrowth of neural tissue (Supplementary Figure 4a). The spinal column of the neural tube was often wrinkled, even in embryos without NTDs (Supplementary Figure 3e).

Given the association of *TP53BP2* deletions with brain structural abnormalities, we wondered whether *TP53BP2* deletions might also be associated with NTDs in humans. We compared the genomic location of human genes orthologous to genes which have been implicated in NTDs in mice with chromosomal bands reported by Tyshchenko et al (1) as associated with NTDs in humans. Interestingly, *TP53BP2* is one of only 16 human genes that lie in these significantly associated bands (Supplementary Figure 5). Deletions of the 1q41-q44 locus encompassing *TP53BP2* are significantly associated with posterior encephalocele, generally considered a NTD (1, 38, 39). This suggests that *TP53BP2* deficiency might also play a role in a subset of human NTDs.

Notably, we found no bias towards females in *Trp53bp2*^{Δ3/Δ3} embryos presenting NTDs, whereas NTDs in p53-null mice occur preferentially in females (Supplementary Figure 4c) (ref. 14). This suggests ASPP2 contributes to NTDs via a p53-independent mechanism. In summary, these results demonstrate that 100% of *Trp53bp2*^{Δ3/Δ3} mice have CNS defects but their phenotypic characteristics vary substantially with the genetic background.

Non-CNS phenotypes overlap between *Trp53bp2*^{Δ3/Δ3} embryos and 1q41q42 microdeletion syndrome patients

Visual inspection of *Trp53bp2*^{Δ3/Δ3} embryos also revealed craniofacial and eye abnormalities (Figure 5a, b). We reported previously that ASPP2-deficient embryos have highly penetrant retinal abnormalities (10). Some B6 *Trp53bp2*^{Δ3/Δ3} embryos lacked one or both eyes (Figure 5a) while others showed coloboma (incomplete eye tissue) or microphthalmia (abnormally small eye(s)) (Figure 5b).

We used microCT and HREM to examine *Trp53bp2*^{Δ3/Δ3} embryos comprehensively for developmental abnormalities. At E13.5 and E14.5, 67-100% of B6 and 33-56% of BALB/c *Trp53bp2*^{Δ3/Δ3} embryos had abnormal heart position involving a 30-45° twist along the coronal axis (Figure 5c) and 67% B6 and 33% BALB/c of *Trp53bp2*^{Δ3/Δ3} embryos had ventricular septal defect (VSD, Figure 5D). Heart function and chamber volumes of adult BALB/c *Trp53bp2*^{Δ3/Δ3} mice were normal (Supplementary Figure 6a). *Trp53bp2*^{Δ3/Δ3} embryos in B6 and mixed backgrounds showed various craniofacial abnormalities including dolichocephaly (an elongation of the head), micrognathia (smaller lower jaw) (Figure 5a, Figure 6) and cleft palate (Figure 5e). A high percentage of embryos also showed gonadal abnormalities resulting in unclear gender at E14.5 (Figure 5f), urethral abnormalities (Figure 5g), abnormal trigeminal nerve and spinal ganglia (Supplementary Figure 6b, c) and multiple other defects of varying penetrance (Figure 6). Notably, 33% of BALB/c *Trp53bp2*^{Δ3/Δ3} embryos lacked a visible abducens nerve.

Embryos with heterozygous deletion of exon 3 (*Trp53bp2*^{Δ3/+}) examined by microCT had 30% incidence of cleft palate in the B6 background, and 30% and 13% incidence of VSD in B6 and BALB/c backgrounds, respectively. While this manuscript was in preparation, the International Mouse Phenotyping Consortium (IMPC, www.mousephenotype.org) – who are performing broad phenotyping for 20 000 mouse genes (3 154, to date) - released phenotypic data on mice with a *Trp53bp2*-exon4-deletion genotype, termed *Trp53bp2*^{tm1b(EUCOMM)Hmgu} (40). Our analysis of this publicly available data showed that this homozygous deletion of *Trp53bp2* exon 4 (*Trp53bp2*^{Δ4/Δ4}) is lethal, with 100% penetrance prior to embryonic day 9 (Supplementary Figure 7a). *Trp53bp2*^{Δ4/+} mice were viable and males showed a significant hyperactive phenotype in the open field test (Supplementary Figure

7b). The *Trp53bp2*^{Δ4/+} males showed no difference in the percentage of time spent in the center of the open field, indicating the phenotype is highly specific to locomotor activation (Supplementary Figure 7b). Of note, these mice also showed lower grip strength normalized by body weight, short tibia, higher bone density and an abnormal glucose response (Supplementary Figure 7c-e). These data from the heterozygotes demonstrate that ASPP2 is haploinsufficient in mouse development.

There is substantial overlap in the phenotypic spectrum – including brain, neurological, craniofacial, eye, heart and urogenital defects - of ASPP2-deficient mice and patients with deletions involving 1q41q42. 50% of patients with *TP53BP2*-deletion had cleft palate, which was observed in 33% and 67% of BALB/c and B6 *Trp53bp2*^{Δ3/Δ3} embryos, respectively. Heart abnormalities, including VSD, were reported for 31% patients with *TP53BP2*-deletion, and 30% B6 *Trp53bp2*^{Δ3/+} embryos had VSD. 1q41q42 microdeletion patients also frequently present with hypotonia and hypoglycemia with hypoglycemic seizures, representing phenotypic overlap with the reduced grip strength and abnormalities in glucose response in *Trp53bp2*^{Δ4/+} mice (see above). Overall, the relative penetrance of defects in *Trp53bp2*^{Δ3/Δ3} embryos also broadly corresponds to the frequency of their occurrence in 1q41q42 deletion patients: virtually all diagnosed cases with 1q41q42 deletions have intellectual disability and/or brain structural abnormalities and there is high penetrance of CNS abnormalities in *Trp53bp2*^{Δ3/Δ3} mice, with lower proportions of 1q41q42 deletion patients and *Trp53bp2*^{Δ3/Δ3} mice having the other phenotypes. These results suggest that *TP53BP2* haploinsufficiency might be implicated in additional abnormalities associated with the 1q41q42 microdeletion syndrome and 1q41q42 deletions more generally.

DISCUSSION

Chromosomal deletion-associated human disorders often have variable phenotypes and severity among individuals, and the vast majority of pathogenic deletions include multiple genes, hampering the identification of causal genes. Experimental model systems are, therefore, needed to aid the identification of causal genes in human developmental disorders. Here we have identified *TP53BP2* as a candidate gene responsible for brain abnormalities in 1q41q42 microdeletion syndrome and show that *ASPP2*-deficient mice also develop CNS abnormalities with 100% penetrance, and phenotypic differences depending on background. Notably, *TP53BP2* is the only gene in the critical region for brain abnormalities of the syndrome for which the gene-deficient mouse model has a CNS phenotype.

Recently, a 1q41q42 microdeletion case with brain abnormalities was reported whose deletion included the last exon of *FBXO28*, suggesting *FBXO28* might also be responsible for these abnormalities (41). A mouse deficient in *FBXO28* is currently unavailable. Importantly, Case 6 in our report (Figure 1, Table S1) showed occipital encephalocele yet harbours a deletion that includes *TP53BP2* but excludes *FBXO28*. *FBXO28* lies outside the existing SRO for brain abnormalities, but it is possible that there are multiple dosage-sensitive genes for brain development in the 1q41q42 region and future studies are needed to investigate this. For example, patients with non-overlapping *DISP1* and *FBXO28* deletions both showed seizures (4, 42), despite the fact that *DISP1* is not contained in the critical region of the syndrome.

Few mouse models exist that are deficient in human 1q4-located genes and phenocopy the abnormalities associated with 1q4 deletions to a significant extent.

The ASPP2-deficient mice described here show craniofacial, eye, heart and urogenital abnormalities in addition to CNS defects, all of which are associated with 1q41q42 deletions. Interestingly, among the 31% of patients with *TP53BP2* deletions who presented with eye abnormalities, strabismus and optic nerve hypoplasia were common. Our HREM analysis of *Trp53bp2*^{Δ3/Δ3} embryos revealed hypoplastic or absent optic nerve and abducens nerve among 33% and 67% of B6 and BALB/c embryos, respectively. Given that the abducens nerve controls eye movement through the lateral rectus muscle, it would be interesting to test whether patients with strabismus and *TP53BP2* deletions have any abducens nerve abnormalities. We note that our ability to determine penetrance precisely is limited by the low number of *Trp53bp2*^{Δ3/Δ3} embryos (n = 3) on the BALB/c background analysed by HREM, due to the demanding nature of this technique. Overall, these observations might explain the significant phenotypic heterogeneity associated with 1q41q42 deletions: there are likely multiple dosage-sensitive genes in the region whose haploinsufficiency is both incompletely penetrant and variably expressed. The observation of NTDs in some of the ASPP2-deficient mice suggests it would be informative to investigate whether mutations involving *TP53BP2* might contribute to NTDs in humans.

To date, three different *Trp53bp2*-deficient mouse lines have been generated: exon 3 deletion mice reported by our group (*Trp53bp2*^{Δ3/Δ3}) (ref. 9), exon 4 deletion mice generated by the International Mouse Knockout Consortium (IKMC) (*Trp53bp2*^{Δ4/Δ4}) (ref. 43), and mice with deletion of exons 10-17 (*Trp53bp2*^{Δ10-17/Δ10-17}) (ref. 8). Homozygous deletion of exon 4 or exons 10-17 is lethal prior to embryonic day 9 with 100% penetrance, whereas deletion of exon 3 results in neonatal lethality with background-dependent penetrance. The exon 3 deletion is

an in-frame deletion causing only the major isoform of *Trp53bp2* to be deleted completely; low levels of shorter forms of *Trp53bp2* can be expressed. Therefore *Trp53bp2*^{Δ3} acts as a hypomorphic allele, which has allowed us to discover developmental effects of ASPP2 deficiency that could not be observed with full-knockout alleles due to their early embryonic lethality.

Imaging of heterozygous *Trp53bp2*^{Δ3/+} embryos showed a lower frequency of structural abnormalities than observed in patients with heterozygous *TP53BP2* deletions. One possible explanation is that the exon 3 deletion is a hypomorphic allele, compared to the complete deletion allele in the patients. In addition, more than one gene is deleted in each 1q41q42 microdeletion. Therefore, the concomitant deletion of multiple haploinsufficient genes might exacerbate the phenotype, as is the case in other known contiguous gene deletion syndromes (44, 45).

At the protein level, the ability of ASPP2 to regulate apicobasal polarity and p53-dependent apoptosis is likely important for its role in neural tube closure. Recently, inappropriate activation of p53 during development was linked with the pathogenesis of CHARGE syndrome, a disorder characterized by abnormalities including developmental delay, heart defects, coloboma, cranial nerve abnormalities, choanal atresia and inner ear abnormalities (44, 45). The phenotypic spectrum in the CHARGE syndrome mouse model shows substantial overlap with the ASPP2-deficient mice (including neural tube defects, short lower jaw, coloboma and heart defects), suggesting dysregulated p53 activity might be responsible for these phenotypes in ASPP2-deficient mice. However, while p53-deficient and p53-overactivated embryos show primarily exencephaly (14, 44), ASPP2-deficient

embryos develop mainly spina bifida or craniorachischisis, pointing to the importance of p53-independent functions of ASPP2.

ASPP2 is also an important regulator of epithelial plasticity and apicobasal polarity (10, 46). Recent studies of Grainyhead-like 2 mutants have shown that dysregulated epithelial mesenchymal transition (EMT) can cause NTDs (47). It is possible that loss of epithelial character together with the loss of apicobasal polarity disrupt neural tube closure in ASPP2-deficient embryos. ASPP2-deficient embryos also showed overgrowth of neural tissue both in the brain and the spinal cord. The surplus of neuroepithelial cells might also contribute to NTDs and potentially other CNS phenotypes in these embryos through mechanical obstruction. Regardless of the exact cellular mechanism, the observed phenotypical similarities between ASPP2 deficiency in mice and humans highlight the importance of ASPP2 in controlling CNS development in both mice and humans.

MATERIALS AND METHODS

Patient recruitment

Patients with 1q4 deletions were enrolled and de-identified data collected following the UK NHS Research Ethics Committee approval (09/H0606/78, Amendment 3), and in accordance with the Institutional Review Board protocols of the participating institutions.

Comparative genomic hybridisation

DNA isolated from patients' blood were analysed by chromosomal microarray following the participating institutions' standard protocols. With the exception of Case 7, all new 1q microdeletion cases have been deposited on the DECIPHER database (<https://decipher.sanger.ac.uk/>).

Brain MRI and morphometry

De-identified brain MRI and/or CT scans were obtained in DICOM format from radiology departments where the scans were recorded. Normal MRI controls used in the preparation of this article were obtained from the Pediatric MRI Data Repository created by the NIH MRI Study of Normal Brain Development. To quantify lateral ventricles (LV) volume, MRI scans were first converted to Nifti format using MRICConvert (University of Oregon, USA; <http://lcni.uoregon.edu/downloads/mriconvert>) and subsequently analysed by ALVIN (48). Multiple scans in each series were used to compute LV volume to produce Figure 2b-left. Axial T1 scans only were used to compute LV volumes for genotype comparison as shown in Figure 2b-right. Out of the fourteen 1q41q42 microdeletion MRI scans, two patient scans (Rosenfeld 9 and Case 7) were unsuitable for morphometry: Case 7 is a prenatal case and the scan for Rosenfeld 9 cannot be converted into Nifti. Therefore, the morphometric analysis of LV volume was performed with 12 patient scans. More information on the NIH cohort is given in Acknowledgments.

Mice

Experiments with mice received UK Home Office approval, Project licence number 30/2862 and fully complied with the UK Home Office guidelines. For this study, *Trp53bp2*^{Δ3} mice in a pure C57BL/6J, mixed C57BL/6Jx129SvJ and pure BALB/c backgrounds were crossed to generate wild type, *Trp53bp2*^{Δ3/+} and *Trp53bp2*^{Δ3/Δ3} embryos (49). Pregnant females were sacrificed at the indicated time points during pregnancy and embryos were collected and genotyped using the following primers: 5'-CTCCACCCCAGGAAATTACA-3' (intron3), 5'-CGGTTTGGAAGTCAAAGGAA-3' (exon 3), and 50-GGACCGCTATCAGGACATA-30 (neomycin resistance gene).

Embryo sexing

The following primers for ZFY were used for sexing by PCR: 5'-GACTAGACATGTCTTAACATCTGTCC-3' and 5'-CCTATTGCATGGACAGCAGCTTATG-3'. The following GAPDH primers were used as controls for the PCR reaction: 5'-TGGCTACAGTAACCGAGTGGT-3' and 5'-CTTTGAGTGGAAGCCGAAGT-3'.

Mouse micro-computed tomography (micro-CT)

Embryos generated from mice as described above were first sacrificed on ice-cold PBS, washed in phenol red-free Hank's salts with EDTA, removed from their yolk sac, their umbilical cord cut, and the freed embryo fixed in 4% formaldehyde for at least 24 h. Each embryo was then immersed in 2 ml Lugol solution (L6146, Sigma-Aldrich, St Louis, MO, USA) for 72 hours at 4°C. All incubations included the replacement of staining solution after the first 24 hours. Four embryos were embedded in 1% agarose (Web Scientific, Crewe, UK) in a dedicated sample holder and scanned using a micro-CT scanner (SkyScan 1172, Bruker, Kontich, Belgium)

at a nominal isotropic pixel size of 4.9 μm (scan parameters: X-ray source voltage – 48 kV; current – 208 mA; filter – a 0.5 mm Al filter; number of projections – 900).

The total scan time was 8 hours for four embryos.

The images projections were reconstructed with the scanner-built-in reconstruction software 'NRecon' and downsampled offline by a factor of two, resulting in a 9.8 μm isotropic voxel size. Image analysis (i.e. 3D segmentation and rendering) was performed in Amira (FEI Ltd, Hillsboro, OR, USA).

High resolution episcopic microscopy

HREM images of E14.5 embryos were obtained as previously described (37). We used the episcopic procedures for sectioning and image capture using a previously described arrangement of microtome and magnification optic (50).

Mouse echocardiography

Adult female Balb/c *Trp53bp2* ^{$\Delta 3/\Delta 3$} mice (n=8) and age matched wild type controls (n=7) received echocardiographic examination at a mean age of 28 weeks. Mice were lightly anaesthetised using 1-1.5% isoflurane in 100% medical oxygen, kept warm on a homeothermic blanket and imaged using a VisualSonics Vevo 2100 (Toronto, Canada) with 22-55 MHz transducer. B-mode trans-thoracic short-axis and long-axis images were obtained to assess left ventricular volumes and function and pulmonary artery Doppler flow as a measure of right-sided function. Images were obtained and analysed using Vevo 2100 v1.6.0 software by a single operator blinded to genotype.

*Trp53bp2 exon 4 deletion mice (*Trp53bp2* ^{$\Delta 4$})*

Publicly available phenotypic data for *Trp53bp2*^{Δ4/Δ4} and *Trp53bp2*^{Δ4/+} mice were mined from the International Mouse Phenotype Consortium (IMPC) URL <https://www.mousephenotype.org/data/genes/MGI:2138319> release 4.3, last updated 12 May 2016, and from Phenoview (<https://www.mousephenotype.org/phenoview>), updated 18 May 2016. Raw data were re-plotted using Graphpad Prism version 6.05 for Windows, (GraphPad Software, La Jolla, CA, USA). Experiment design by IMPC followed protocols of the International Mouse Phenotyping Resource of Standardized Screens (IMPreSS) (<https://www.mousephenotype.org/impress>). For statistical testing, results from IMPC's Mixed Model framework, linear mixed-effects model were adopted. P values below 0.05 were deemed significant.

Visualization and statistical analysis

Data for panels in Figure 1a and 1c; were generated using the UCSC Genome Browser (<http://genome.ucsc.edu/>) (51), genome release hg19. Plots in panels Figure 1b, 2b, Supplementary Figure 1b and Supplementary Figure 7a-d were generated using Graphpad Prism version 6.05 for Windows, (GraphPad Software, La Jolla, CA, USA). Chromosome plots in Figure S5 were generated using Phenogram (<http://visualization.ritchielab.psu.edu/phenograms/plot>) (52). Statistical tests were performed in Graphpad Prism (see above) and R (53).

AUTHOR CONTRIBUTIONS

JZ and XL designed the study; JZ, VV, DS, AV, JES, PM, ES, FP, CAL, and TJM performed the experiments; SJ, YL, EC, LFE, MT, ASA, HD, TAC, JA, ADC, EH, DK, DAS, MJP, ZZ, YSC, DW, AMI, KRJ, SZ contributed clinical data; JZ, PP, JAR analysed clinical data, JZ, VV and XL wrote the paper; all authors analysed data and reviewed the manuscript.

ACKNOWLEDGMENTS

This work was funded by the Ludwig Institute for Cancer Research. JZ is supported by the Skaggs-Oxford Scholarship (The Scripps Research Institute). JES acknowledges support from the BHF (FS/11/50/29038), and the BHF Centre of Research Excellence, Oxford (RE/08/004). We thank Mary Muers and Andrew Wilkie for critical reading of the manuscript, and Michael Schocke for radiological assistance. This study makes use of data generated by the DECIPHER community. A full list of centres who contributed to the generation of the data is available from <http://decipher.sanger.ac.uk> and via email from decipher@sanger.ac.uk. Funding for the DECIPHER project was provided by the Wellcome Trust. Normal MRI controls used in the preparation of this article were obtained from the Pediatric MRI Data Repository. This is a multi-site, longitudinal study of typically developing children, from ages newborn through young adulthood, conducted by the Brain Development Cooperative Group and supported by the National Institute of Child Health and Human Development, the National Institute on Drug Abuse, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke (Contract #s N01-HD02-3343, N01-MH9-0002, and N01-NS-9-2314, -2315, -2316, -2317, -2319 and -2320). A listing of the participating sites and a complete

listing of the study investigators can be found at
http://www.bic.mni.mcgill.ca/nihpd/info/participating_centers.html. This manuscript
reflects the views of the authors and may not reflect the opinions or views of the
NIH.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

SUPPLEMENTARY INFORMATION

Supplementary information is available at Cell Death and Differentiation's website.

REFERENCES

1. Tyshchenko N, Lurie I, Schinzel A. Chromosomal map of human brain malformations. *Hum Genet.* 2008;124(1):73-80.
2. Brewer C, Holloway S, Zawalnyski P, Schinzel A, FitzPatrick D. A Chromosomal Deletion Map of Human Malformations. *Am J Hum Genet.* 1998;63(4):1153-9.
3. Rosenfeld JA, Lacassie Y, El-Khechen D, Escobar LF, Reggin J, Heuer C, et al. New cases and refinement of the critical region in the 1q41q42 microdeletion syndrome. *Eur J Med Genet.* 2011;54(1):42-9.
4. Au PYB, Argiropoulos B, Parboosingh JS, Micheil Innes A. Refinement of the critical region of 1q41q42 microdeletion syndrome identifies FBXO28 as a candidate causative gene for intellectual disability and seizures. *Am J Med Genet A.* 2014;164(2):441-8.
5. Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E, et al. CDK-mediated activation of the SCFFBXO28 ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. *EMBO Molecular Medicine.* 2013;5(7):1067-86.
6. Gorina S, Pavletich NP. Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2. *Science.* 1996;274(5289):1001-5.
7. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh J-K, Zhong S, et al. ASPP Proteins Specifically Stimulate the Apoptotic Function of p53. *Mol Cell.* 2001;8(4):781-94.
8. Kampa KM, Acoba JD, Chen D, Gay J, Lee H, Beemer K, et al. Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have

attenuated cellular damage–response thresholds. *P Natl Acad Sci USA*. 2009;106(11):4390-5.

9. Vives V, Su J, Zhong S, Ratnayaka I, Slee E, Goldin R, et al. ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. *Gene Dev*. 2006;20(10):1262-7.
10. Sottocornola R, Royer C, Vives V, Tordella L, Zhong S, Wang Y, et al. ASPP2 Binds Par-3 and Controls the Polarity and Proliferation of Neural Progenitors during CNS Development. *Dev Cell*. 2010;19(1):126-37.
11. Bergamaschi D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. ASPP1 and ASPP2: Common Activators of p53 Family Members. *Mol Cell Biol*. 2004;24(3):1341-50.
12. Gao Y, Chen X, Shangguan S, Bao Y, Lu X, Zou J, et al. Association Study of PARD3 Gene Polymorphisms With Neural Tube Defects in a Chinese Han Population. *Reprod Sci*. 2012;19(7):764-71.
13. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High-frequency developmental abnormalities in p53-deficient mice. *Curr Biol*. 1995;5(8):931-6.
14. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. *Nat Genet*. 1995;10(2):175-80.
15. Gu X, Xing L, Shi G, Liu Z, Wang X, Qu Z, et al. The circadian mutation PER2(S662G) is linked to cell cycle progression and tumorigenesis. *Cell Death Differ*. 2012;19(3):397-405.
16. Eom DS, Amarnath S, Agarwala S. Apicobasal polarity and neural tube closure. *Dev Growth Differ*. 2013;55(1):164-72.
17. Monier B, Gettings M, Gay G, Mangeat T, Schott S, Guarner A, et al. Apico-basal forces exerted by apoptotic cells drive epithelium folding. *Nature*. 2015;518(7538):245-8.
18. Yamaguchi Y, Shinotsuka N, Nonomura K, Takemoto K, Kuida K, Yosida H, et al. Live imaging of apoptosis in a novel transgenic mouse highlights its role in neural tube closure. *J Cell Biol*. 2011;195(6):1047-60.
19. Shaffer LG, Theisen A, Bejjani BA, Ballif BC, Aylsworth AS, Lim C, et al. The discovery of microdeletion syndromes in the post-genomic era: review of the methodology and characterization of a new 1q41q42 microdeletion syndrome. *Genet Med*. 2007;9(9):607-16.
20. Mazzeu JF, Krepschi-Santos AC, Rosenberg C, Szuhai K, Knijnenburg J, Weiss JMM, et al. Chromosome abnormalities in two patients with features of autosomal dominant Robinow syndrome. *Am J Med Genet A*. 2007;143A(15):1790-5.
21. Mazzeu JF, Vianna-Morgante AM, Krepschi ACV, Oudakker A, Rosenberg C, Szuhai K, et al. Deletions encompassing 1q41q42.1 and clinical features of autosomal dominant Robinow syndrome. *Clin Genet*. 2010;77(4):404-7.
22. Rice GM, Qi Z, Selzer R, Richmond T, Thompson K, Pauli RM, et al. Microdissection-based high-resolution genomic array analysis of two patients with cytogenetically identical interstitial deletions of chromosome 1q but distinct clinical phenotypes. *Am J Med Genet A*. 2006;140A(15):1637-43.
23. Filges I, Röthlisberger B, Boesch N, Weber P, Wenzel F, Huber AR, et al. Interstitial deletion 1q42 in a patient with agenesis of corpus callosum: Phenotype–genotype comparison to the 1q41q42 microdeletion suggests a contiguous 1q4 syndrome. *Am J Med Genet A*. 2010;152A(4):987-93.
24. Spreiz A, Haberlandt E, Baumann M, Baumgartner Sigl S, Fauth C, Gautsch K, et al. Chromosomal microaberrations in patients with epilepsy, intellectual disability, and congenital anomalies. *Clin Genet* 2014;86(4):361-6.
25. Christensen RD, Yaish HM. A neonate with the Pelger-Huet anomaly, cleft lip and palate, and agenesis of the corpus callosum, with a chromosomal microdeletion involving 1q41 to 1q42.12. *J Perinatol*. 2012;32(3):238-40.
26. Wat MJ, Veenma D, Hogue J, Holder AM, Yu Z, Wat JJ, et al. Genomic alterations that contribute to the development of isolated and non-isolated congenital diaphragmatic hernia. *J Med Genet*. 2011;48(5):299-307.

27. Ono Y, Sorimachi H. Calpains — An elaborate proteolytic system. *Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics*. 2012;1824(1):224-36.
28. Takano J, Mihira N, Fujioka R, Hosoki E, Chishti AH, Saido TC. Vital Role of the Calpain-Calpastatin System for Placental-Integrity-Dependent Embryonic Survival. *Mol Cell Biol*. 2011;31(19):4097-106.
29. Dutt P, Croall D, Arthur JS, Veyra TD, Williams K, Elce J, et al. m-Calpain is required for preimplantation embryonic development in mice. *BMC Dev Biol*. 2006;6(1):3.
30. Hata S, Abe M, Suzuki H, Kitamura F, Toyama-Sorimachi N, Abe K, et al. Calpain 8/nCL-2 and Calpain 9/nCL-4 Constitute an Active Protease Complex, G-Calpain, Involved in Gastric Mucosal Defense. *PLoS Genet*. 2010;6(7):e1001040.
31. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue Expression (GTEx) project. *Nat Genet*. 2013;45(6):580-5.
32. Hawrylycz M, Ng L, Feng D, Sunken S, Szafer A, Dang C. The Allen Brain Atlas. In: Kasabov N, editor. *Springer Handbook of Bio-/Neuroinformatics*: Springer Berlin Heidelberg; 2014. p. 1111-26.
33. Miller JA, Ding S-L, Sunken SM, Smith KA, Ng L, Szafer A, et al. Transcriptional landscape of the prenatal human brain. *Nature*. 2014;508(7495):199-206.
34. Coe BP, Witherspoon K, Rosenfeld JA, van Bon BWM, Vulto-van Silfhout AT, Bosco P, et al. Refining analyses of copy number variation identifies specific genes associated with developmental delay. *Nat Genet*. 2014;46(10):1063-71.
35. Cooper GM, Coe BP, Girirajan S, Rosenfeld JA, Vu TH, Baker C, et al. A copy number variation morbidity map of developmental delay. *Nat Genet*. 2011;43(9):838-46.
36. Shaikh TH, Gai X, Perin JC, Glessner JT, Xie H, Murphy K, et al. High-resolution mapping and analysis of copy number variations in the human genome: A data resource for clinical and research applications. *Genome Res*. 2009;19(9):1682-90.
37. Weninger WJ, Meng S, Streicher J, Mueller GB. A new episcopic method for rapid 3-D reconstruction: Applications in anatomy and embryology. *Anat Embryol*. 1998;197(5):341-8.
38. Rowland CA, Correa A, Cragan JD, Alverson CJ. Are Encephaloceles Neural Tube Defects? *Pediatrics*. 2006;118(3).
39. National Guideline C. Neural tube defects. Rockville MD: Agency for Healthcare Research and Quality (AHRQ).
40. Brown SDM, Moore MW. The International Mouse Phenotyping Consortium: past and future perspectives on mouse phenotyping. *Mammalian Genome*. 2012;23(9):632-40.
41. Cassina M, Rigon C, Casarin A, Vicenzi V, Salviati L, Clementi M. FBXO28 is a critical gene of the 1q41q42 microdeletion syndrome. *Am J Med Genet A*. 2015;167(6):1418-20.
42. Jun KR, Hur YJ, Lee JN, Kim HR, Shin JH, Oh SH, et al. Clinical characterization of DISP1 haploinsufficiency: A case report. *Eur J Med Genet*. 2013;56(6):309-13.
43. The International Mouse Knockout C. A Mouse for All Reasons. *Cell*. 2007;128(1):9-13.
44. Van Nostrand JL, Brady CA, Jung H, Fuentes DR, Kozak MM, Johnson TM, et al. Inappropriate p53 activation during development induces features of CHARGE syndrome. *Nature*. 2014;514.
45. Sanlaville D, Verloes A. CHARGE syndrome: an update. *Eur J Hum Genet*. 2007;15(4):389-99.
46. Wang Y, Bu F, Royer C, Serres S, Larkin JR, Soto Manuel S, et al. ASPP2 controls epithelial plasticity and inhibits metastasis through β -catenin-dependent regulation of ZEB1. *Nat Cell Biol*. 2014;16(11):1092-104.
47. Ray HJ, Niswander LA. Grainyhead-like 2 downstream targets act to suppress EMT during neural tube closure. *Development*. 2016.
48. Kempton MJ, Underwood TSA, Brunton S, Stylios F, Schmechtig A, Ettinger U, et al. A comprehensive testing protocol for MRI neuroanatomical segmentation techniques:

Evaluation of a novel lateral ventricle segmentation method. *NeuroImage*. 2011;58(4):1051-9.

49. Sottocornola R, Royer C, Vives V, Tordella L, Zhong S, Wang Y, et al. ASPP2 binds Par-3 and controls the polarity and proliferation of neural progenitors during CNS development. *Dev Cell*. 2010;19(1):126-37.

50. Mohun TJ, Leong LM, Weninger WJ, Sparrow DB. The Morphology of Heart Development in *Xenopus laevis*. *Dev Biol*. 2000;218(1):74-88.

51. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The Human Genome Browser at UCSC. *Genome Res*. 2002;12(6):996-1006.

52. Wolfe D, Dudek S, Ritchie M, Pendergrass S. Visualizing genomic information across chromosomes with PhenoGram. *BioData Min*. 2013;6(1):18.

53. Team RDC. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria 2008.

FIGURE LEGENDS

Figure 1. *TP53BP2* is deleted in 1q41q42 microdeletion patients with brain abnormalities

(a) Genomic locations of 1q41q42 deletions from new and published patients. Red indicates brain morphological abnormalities were reported for the patient, green indicates absence of reported brain abnormalities. The positions of the *CAPN8*, *CAPN2*, *TP53BP2* and *FBXO28* genes are marked with black arrows; black line further marks the position of *TP53BP2*. **FBXO28* is not contained in the smallest region of overlap (SRO) of patient deletions with brain abnormalities. Panel generated using UCSC genome browser (<http://genome.ucsc.edu>), hg19 assembly.

(b) The proportions of cases with and without *TP53BP2* deletion with and without brain abnormalities. (c) Focus on the SRO of patient deletions with brain morphological abnormalities. Patients with abnormal ventricles are marked purple.

Figure 2. Enlarged ventricles and other abnormalities in patients with *TP53BP2* deletions

(a) Summary of the patient records analysed in this study. (b) Quantification of lateral ventricle volume by probabilistic morphometry. Volumes were computed by ALVIN on all suitable scans in each MRI series, from 1q41q42 microdeletion patients with and without *TP53BP2* deletion. Left panel – T1 and T2 sagittal, axial and coronal scans were used for computations of LV volumes, bars showing mean \pm s. d.; right panel – T1 axial scans used only; each data point showing a mean from T1 axial scans for each patient. MRI scans of 12 patients and a group of 28 healthy pediatric individuals (NIH controls) were used. Median age of microdeletion cohort

= 19 months, median of NIH controls = 15 months. For statistical comparison of LV volumes in patient groups, values were first tested for normality by the D'Agostino and Pearson omnibus test, then compared to NIH controls using two-tailed student's t-test and corrected for multiple hypothesis testing by multiplying the p-value by the number of tests. Mean \pm s. d. shown. (c) Axial and sagittal MRI images of brains of 1q41q42 microdeletion patients. T1 non-contrast images are shown, except for cases where only T2 scans were available (Rosenfeld Subject 14, Spreiz et al, 2014 and Case 7). Double white arrowheads: hypoplasia of corpus callosum; single white arrowheads: asymmetry in lateral ventricle size; yellow asterisk: mega cisterna magna.

Figure 3. *Trp53bp2* ^{$\Delta 3/\Delta 3$} and *Trp53bp2* ^{$\Delta 3/+$} mice have CNS defects

(a) Gross dilation of lateral ventricles is visible in *Trp53bp2* ^{$\Delta 3/\Delta 3$} embryos, resulting in bulging foreheads. Intraventricular hemorrhage is frequently seen (white arrows). (b) Present and absent pineal gland (red arrows) in wild type and *Trp53bp2* ^{$\Delta 3/\Delta 3$} embryos, respectively as seen in a single HREM section. (c) Surface rendering of lateral ventricles in 1q41q42 microdeletion patients from (left, constructed from MRI scans) and *Trp53bp2* ^{$\Delta 3/\Delta 3$} vs wild-type embryos (right, constructed from microCT scans). (d) Brain abnormalities in heterozygous *Trp53bp2* ^{$\Delta 3/+$} embryos. Left: Asymmetry of lateral ventricles in heterozygous *Trp53bp2* ^{$\Delta 3/+$} embryo caused by a structural abnormality (red arrow). MicroCT image shown. Right: asymmetry in neuroepithelial tissue distribution in the brain (red arrow) and the associated subcranial haemorrhage (white and red arrows) in a BALB/c *Trp53bp2* ^{$\Delta 3/+$} embryo.

734

735 **Figure 4. *Trp53bp2*^{Δ3/Δ3} mice have neural tube defects**

736 Strain dependence of NTD penetrance in *Trp53bp2*^{Δ3/Δ3} mice: Embryo phenotypes
737 in pure C57BL/6 (left), mixed 129Sv - C57BL/6 (middle), and BALB/c (right)
738 background embryos range in severity from small exencephaly (right, white arrow)
739 to severe craniorachischisis (left upper panel, white arrows). Spina bifida is also
740 observed in the mixed (middle panels, white arrows) and B6 (left lower panel, white
741 arrow) backgrounds.

742

743 **Figure 5. ASPP2-deficient mice have non-CNS phenotypes**

744 (a) Craniofacial abnormalities in *Trp53bp2*^{Δ3/Δ3} E14.5 embryos include
745 dolichocephaly and hypoplasia or agenesis of the lower jaw (white arrows) (b) Eye
746 abnormalities observed in *Trp53bp2*^{Δ3/Δ3} mice feature coloboma (top, missing tissue
747 indicated by red arrow) and microphthalmia (bottom) in E14.5 embryos. (c)
748 Abnormal heart position is seen in all B6 embryos examined. The microCT-based
749 3D reconstruction shows the heart is twisted approximately 45 degrees along the
750 coronal axis (top panel), sometimes resulting in an altered direction of the ductus
751 arteriosus with respect to the aorta (axial view, white arrow). Colour coding: yellow
752 – right ventricle; pink – left ventricle; blue trachea; red – aorta; light green – ductus
753 arteriosus. (d) Ventricular septal defect in *Trp53bp2*^{Δ3/Δ3} E14.5 embryonic heart (red
754 arrow); shown on a representative HREM section. (e) Palate (red arrows) showing
755 cleft palate in *Trp53bp2*^{Δ3/Δ3} E14.5 embryo. (f) Largest-area HREM section of
756 gonads (red arrows) showing abnormalities and unclear gender in a *Trp53bp2*^{Δ3/Δ3}

E14.5 embryo vs male E14.5 wild-type embryo. (g) Single vs double ureter (red arrows) in wild type vs *Trp53bp2*^{Δ3/Δ3} E14.5 embryos, respectively as visible by HREM.

Figure 6. Summary of phenotypes in *Trp53bp2*^{Δ3/Δ3} and *Trp53bp2*^{Δ3/+} embryos

Abnormalities detected by naked eye (visual inspection), microCT and HREM in E13.4 and E14.5 ASPP2-deficient embryos. Frequency and the number of embryos evaluated for each phenotype are given. Wild-type littermate embryos were used as reference controls. In the case of BALB/c embryos, eye abnormalities were difficult to determine visually and therefore quantified for a small number of embryos.